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MCF-7 cells in the presence of antiestrogen tamoxifen, we inves-
tigated the possible changes in the hormonal sensitivity of these
cells caused by the co-cultivation in vitro. For this purpose
MCF-7/T cells were transfected with the plasmid containing
the gene of the green fluorescent protein (GFP), and GFP-positive
hormone-resistant subline MCF-7/T/GFP+ was developed. The
GFP expression should allow to distinguish the resistant and
parental cells during co-cultivation.
To study the influence of the co-cultivation on the cell sensi-
tivity to tamoxifen the parent MCF-7 cells (GFP-negative) were
co-cultivate with the resistant MCF-7/T/GFP+/cells for 10 days,
then the cells were treated with tamoxifen and the efficiency of
growth inhibitory tamoxifen action was determined. We found,
that the co -cultivation of the parent and resistant cells lead to
increase in the resistance of the parent cell to tamoxifen, indicat-
ing the important role of the contacts, direct or indirect, between
hormone sensitive and resistant cells in the development of
hormone resistance.
In general, we evaluate the established results as the first evi-
dence of the possible involvement of the cell–cell underrelations
in the realization of the hormonal response, and suppose that
the next investigations will give a new insights in the molecular
mechanisms of this effects and its role in the formation of the
hormone-resistant phenotype of the tumors.
The work was supported by the Russian Science Foundation, grant
No. 14–15-00362.
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Orthopedic oncologic prostheses are essential in postoperative
therapy and improvement of life quality of oncological patients.
However, construction and composition of implants has to be
improved for better biocompatibility and reduction of inflamma-
tory responses. The materials based on polylactic acid (PLA) and
hydroxyapatite (HA) have been suggested as promising solution
for implant coating in order to improve reconstruction of bone
defects, to reduce risk of inflammation and implant rejection.
Objective: To obtain the bioresorbable composites using bio-
compatible poly-L-lactide (PLA) with HA and to evaluate its effect
on bone remodeling rate.
Materials and methods: After dissolution of PLA* in chloroform
the powder-like HA (d = 20–40 nm) was added under vigorous
stirring (PLA: HA = 75:25). The PLA/HA suspension was sonicated
(40 kHz) and precipitated in ethanol. Fine fibers (d = 0.1– 0.5 lm,
of more than 2 mm length) were formed. The PLA/HA composite
fibers were air-dried; they consisted of HA nanoparticles homoge-
neously distributed in the PLA matrix. The composites ability to
participate in bone remodeling was estimated by determination
of the polymer matrix dissolution rate and by formation of the
CPL on the surface of the composites.
Results: The degradation rate of the polymer matrix was calcu-
lated by measuring concentration of lactic acid (by HPLC method),
being released from PLA macromolecules as the result of the
hydrolysis in the physiologic solution (pH 7, x(NaCl) = 0.9%). The
PLA degradation rate during the first 4 days of soaking of the sub-
strates (d = 10 mm, S = 190 mm2, m = 0.20 ± 0.01 g) in the solution
is rather high (Clactic acid = 10 wt%), while on day 5 it decreases
and stays constant during the rest of the time. The HA content
increase in the composite results in the enhanced hydrolysis of
PLA, caused both by the partial acid-base interaction between
PLA and HA, and due to presence of the phase boundaries. Inter-
esting to note that pure PLA (without HA) is hardly hydrolyzed in
the physiologic solution even on the 30-th day of the experiment.
Formation of calcium phosphate layer (CPL) was done in the SBF
media, simulating the mineral constituents of the blood plasma
at 37 C, over 28 days period. The total concentration of Ca2+
and Mg2+ ions in the SBF-solution was determined by daily
trilonometry in the ammonia buffer with eriochrome black T as
indicator. This investigation clearly shows that the substrates
both of HA and PLA/HA promote the CLP formation on their sur-
faces. On day 14 of the substrates soaking in the SBF solution the
increment of Ca2+, Mg2+ ions adsorbed on the HA substrate rose
to the value of m (Ca2+ + Mg2+)/VSBF = 0.11 mg/l, while the same
value on the composite PLA/HA substrate was 0.06 mg/l. Thus the
rate of adsorption of Ca2+ ions on the surface of HA is higher than
that on the surface of the PLA/HA substrates. It is the result of the
high HA content in the material. Pure PLA does not promote
adsorption of Ca2+ and Mg2+ ions from the SBF media. Thus
the HA particles incorporated in the PLA matrix may cause fast
the CLP formation improving the ossification in the bone recon-
struction processes. Biocompatibility and anti-inflammatory
activity of PLA, HA and PLA/HA composite was studied in a pilot
experiment in the cell-mediated immune response of individual
donors in vitro using CD14+ human monocytes. Insignificant
pro-inflammatory cytokine secretion of the M1 type (TNFa) is
observed in the presence of PLA, while HA and PLA/HA
composites don’t contribute to their release. The PLA promotes
the release of M2 cytokine CCL18 on day 6 of macrophage
culturing suggesting potential anti-inflammatory properties of
the material.
Conclusion: The composite PLA/HA supports active bone-like
layer formation on its surface improving ossification in the bone
reconstruction process. The pilot experiment suggested that
PLA/HA does not cause inflammatory reactions, while PLA can
potentially regulate the balance between M1/M2 reaction to
suppress unnecessary inflammation.
*Mol. mass ca 60 kDa, prepared in the Laboratory of Catalytic
Research of Tomsk State University.
This Research is supported by Tomsk State University Competitive-
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and EU IMMODGEL project, Grant No. (602694). Work was conducted
EJC SUPPLEMENTS 13 (2015) 1–75 49
with the application of the Tomsk regional common use center
technical equipment acquired thanks to a grant of the
Russian Ministry of the Agreement No. 14.594.21.0001
(RFMEFI59414X0001).
http://dx.doi.org/10.1016/j.ejcsup.2015.08.088
P13
Features of proteasome system functioning in the tumor and
microenvironment cells of breast cancer
E. Shashovaa,*, E. Kolegovaa,b, Yu. Lyupinac, E. Slonimskayaa,b,
I. Kondakovaa, N. Sharovac. aTomsk Cancer Research Institute,
Tomsk, Russian Federation, bSiberian State Medical University,
Tomsk, Russian Federation, cNK Koltsov Institute of Developmental
Biology of Russian Academy of Sciences, Moscow, Russian Federation
⇑
Corresponding author.
Background: The tumor microenvironment plays an important
role in the progression of cancer and may be regulated by prote-
olysis, including the proteasomes. The proteasomes modify the
biologically important molecules involved in the pathogenesis
and progression of a variety of malignancies, including breast
cancer (BC). The aim of this study was to investigate the features
of the subunit composition of proteasomes in the tumor and its
microenvironment of breast cancer.
Material and Methods: Thematerial for investigation was sam-
ples of tumor tissue of invasive ductal breast cancer. The study
was conducted to estimate the distribution of the total pool of
proteasome, proteasomes activator PA700, immune proteasome
forms containing LMP7 and/or LMP2 subunit in tumor cells and
stromal component using immunofluorescence. Furthermore,
there was evaluated the distribution of the proteasome in the
tumor. The expression of immune proteasomes and proteasomes
activators in the cells was studied by immunofluorescence label-
ing of the cells by antibodies to immune proteasome subunits and
cell markers. Fluorescence was analyzed by using a fluorescence
microscope DM RXA2 (‘‘Leica”, Germany) and confocal micro-
scope TCS SP (‘‘Leica”, Germany). The specificity of the primary
antibodies was confirmed by check samples, at which the
reaction was carried out only with the second antibody. No cross
reaction between the first and second antibodies was tested by
incubation of each primary antibodies with the opposing second
antibodies. In addition, there was carried out labeling the cell
nuclei by reagent Hoechst 33,342.
Results: It was found that the tumor cells comprise immune
proteasomes, also PA700 and PA28ab activators. Activator PA28ab
and immune proteasomes are localized in the cytoplasm of tumor
cells, whereas a1, 2, 3, 5, 6, 7 subunits and PA700 activator
detected in the cytoplasm and in the nuclei of tumor cells. Avail-
ability of a1, 2, 3, 5, 6, 7 subunits in the nuclei of tumor cells shows
the expression of constitutive proteasome subunits. Stromal cells
are characterized by a high ratio of the a1, 2, 3, 5, 6, 7 subunits to
the immune LMP2 subunit as compared to cells of invasive ductal
carcinoma. This means that the pool of proteasome in tumor cells
of invasive ductal cancer is enriched by the immune proteasomes
as compared to stromal cells. Thus, samples of invasive ductal
breast cancer contain predominantly tumor cells enriched by
immune proteasomes, activators PA700 and PA28ab. The presence
of proteasomes in stromal component indicates that the tumor
microenvironment also has active processes of proteolysis, with
involving proteasome system. Probably the processes occurring
in the stromal component contribute to the output of the
proteasome into the extracellular space, which is confirmed by
other researchers about the existence of circulating proteasome
pools and their further participation in dissemination of cancer.
This work was supported by the Russian Foundation for Basic
Research (Grant numbers 13-04-00169).
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Background: Metformin is a antidiabetic drug with anticancer
properties. However, the mechanism action by which metformin
affects various cancer cells still unknown. It is known that tumor
growth is accompanied by changes in the metabolic cascade that
includes overproduction of lactate and adenosine. The adenosine
is released into the extracellular environment and regulates
differentiation, proliferation, and angiogenesis of tumor mass.
We found that lactate is activator of key enzyme of adenosine
metabolism – adenosine deaminase (ADA).
Aim: The aim of our study was to investigate the catabolism of
adenosine in the tumor while taking metformin.
Materials and methods: In this study we investigated the level
of adenosine, inosine, hypoxanthine and ADA activity in 15
women aged 46–76 years, with breast cancer (BC) T2-4N1M0 (can-
cer tissues) during treatment with metformin, 1000 mg per day
for 3 months. Control group – 15 women aged 46–76 years, with
stage T2-4N1M0 breast cancer (cancer tissues) without metformin
therapy.
Statistical analysis was performed using the license package
StatSoft. Statistica 12.0.
Results: ADA activity during treatment with metformin was 2-
fold increased: 12.1 ± 2.49 nmol/min*mg in comparison with 4.77
± 0.943 nmol/min*mg. Concentration of catabolic products of ade-
nosine degradation was increased before metformin therapy. Ino-
sine level was 0.121 ± 0.041 micro mol/g tissue (BC tissues from
women without metformin 0.042 ± 0.015 micro mol/g tissue).
Hypoxanthine 2.45 ± 0.428 micro mol/g tissue (in comparison
with 0.711 ± 0.269 micro mol/g tissue). Whereas, adenosine level
in BC after metformin therapy was 0.226 ± 0.148 micro mol/g tis-
sue (in comparison with 0.186 ± 0.056 micro mol/g tissue), that
were not significantly different.
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